The biotech IPO market continues to charge full-steam ahead, with three more companies submitting their Nasdaq pitches to the SEC late Friday.
The leaders among the pack are Adagio Therapeutics and Castle Creek Biosciences, each penciling in $100 million initially. Following up the rear is Eliem Therapeutics, jotting down $80 million for its raise estimate less than six months after launching out of RA Capital’s incubator.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,